Accelero Capital Revenue and Competitors
Estimated Revenue & Valuation
- Accelero Capital's estimated annual revenue is currently $936k per year.
- Accelero Capital's estimated revenue per employee is $78,000
Employee Data
- Accelero Capital has 12 Employees.
- Accelero Capital grew their employee count by 20% last year.
Accelero Capital's People
Name | Title | Email/Phone |
---|
Accelero Capital Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.8M | 27 | -4% | $15.7M | N/A |
#2 | $25.5M | 178 | -3% | N/A | N/A |
#3 | $1.4M | 22 | -50% | $21.2M | N/A |
#4 | $56.6M | 348 | 19% | $6M | N/A |
#5 | $6.3M | 56 | -21% | $216.8M | N/A |
#6 | $0M | 2 | 0% | $33.3M | N/A |
#7 | $33.3M | 233 | 0% | N/A | N/A |
#8 | $32.4M | 232 | -26% | $64.6M | N/A |
#9 | $30M | 215 | -22% | $46.8M | N/A |
#10 | $261.6M | 1407 | 15% | $75M | N/A |
What Is Accelero Capital?
Accelero Capital is an investment and management group focused on telecommunication, digital media and technology. Accelero Capital`s management team has an unparalleled track record in strategic, operational and financial management. It leverages its expertise and sector know-how to identify high-growth assets and assets with turnaround potential.
keywords:N/AN/A
Total Funding
12
Number of Employees
$936k
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Accelero Capital News
2022-04-13 - Global Aptamers: Therapeutics, Technologies and Services ...
2bind; Accelero Bioanalytics; Achiko; Acuitas Capital; Admera Health; Aju IB; Allergan; Amgen; ASKA Pharmaceutical; AstraZeneca; blueconic...
2022-04-06 - Global Targeted Protein Degradation (TPD) Market ...
... Venture capital financing of TPD technology companies ... AbbVie; Accelero Biostructures; Amgen; Amphista Therapeutics; AnHorn Medicines...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 12 | 0% | N/A |
#2 | $1.5M | 12 | -40% | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |